Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J’s Spravato Gets EU Okay For Drug-Resistant Depression

Nasal Spray Completes Approval Process Unscathed

Executive Summary

Concerns that written interventions might delay the expected EU approval of the novel ketamine-based antidepressant have come to naught.

You may also be interested in...



EU Approval Delay for Janssen’s Spravato?

The EMA has received written interventions from third parties relating to its CHMP opinion that the controversial antidepressant should receive EU approval.

AstraZeneca's Fredrickson On Its Cancer Ambitions

Just over a year ago, AstraZeneca at last returned to growth and set about a reorganization that placed oncology at the heart of its plans for continued success. In Vivo talked to the executive vice-president of its Oncology Business Unit David Fredrickson about how the company hopes to become a major cancer player.

Lynparza Gets US OK For Pancreatic Cancer

The leading PARP inhibitor gets a new tumor type added to its label after a narrow ODAC vote in favor less than a fortnight ago.

Topics

Related Companies

UsernamePublicRestriction

Register

SC141385

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel